Concerns & Risks -- 7/10
ResMed's fiscal year ends June 30, so FY+1 = FY2027 (Jul 2026 - Jun 2027). The right lens for a mature, cash-generative medtech leader is forward P/E; EV/Revenue is secondary given the SaaS sliver.
| Metric | RMD Multiple | Peer Avg | Read |
|---|---|---|---|
| P / EPS (FY2027) — PRIMARY | ~17.9x | ~20-22x | Below peers & below ~30x own history |
| EV / Revenue (FY2027, secondary) | ~4.7x | ~5-6x | Below large-cap MedTech |
| EV / EBITDA (TTM, context) | 12.8x | ~16-18x | Discounted |
| # | Catalyst | Detail |
|---|---|---|
| 1 | GLP-1 Inflection (Headwind to Tailwind) | Claims data on 1.95M patients show GLP-1 + CPAP patients start CPAP 10-11% more and resupply 6.2% more at 3 years (first 3-yr data, Q2 FY26). The single biggest sentiment-inverting catalyst. |
| 2 | Margin Expansion Runway | 310bps YoY gross-margin expansion in Q2 FY26; FY26 GM guided 62-63%; CEO committed to double-digit-bps GM improvement every year through 2030. |
| 3 | Competitive-Bidding Overhang Removed | For the first time in 15 years, CPAP/APAP/bilevel are excluded from the CMS competitive-bidding program — a clean removal of a recurring US reimbursement risk. |
| 4 | New-Product Cycle | F30i Comfort / F30i Clear full-face fabric masks (high-price, high-margin) rolling out globally; first FDA-cleared AI device (Comfort Match); Dawn AI assistant scaling. |
| 5 | RCS Software Reacceleration | Portfolio management to take RCS from mid-single-digit back to high-single-digit growth plus double-digit op-profit growth by FY2027. |
| 6 | Capital Return | Buyback raised to above $600M for FY26; net-cash balance sheet (~$753M net cash); dividend raised 13%. |
| # | Risk | Severity | Detail |
|---|---|---|---|
| 1 | Tariffs (Section 232 medical-supplies probe) | LOW | Products have qualified for global tariff relief for decades under the Nairobi Protocol (chronic respiratory disability); US manufacturing doubling (Calabasas) + new Indianapolis DC de-risk further. |
| 2 | Global Minimum Tax | LOW-MEDIUM | Effective tax rate lifted to 21-23% (from 18-19% prior) — a modest, known EPS drag, partly offset by a Singapore refundable investment credit. |
| 3 | CMS Competitive Bidding | RESOLVED | Key category excluded for the first time in 15 years — a positive removal of a recurring reimbursement risk. |
| 4 | China / Geopolitical | LOW | China is low-single-digit % of revenue and a sales channel only (manufacturing is US, Singapore, Thailand). Minimal supply/geopolitical dependency. |
| # | Factor | Detail |
|---|---|---|
| 1 | Dominant Leader, Undersupplied TAM | Above-50%-US-share leader in an under-20%-penetrated, structurally growing market — the binding constraint is diagnosis, not competition. |
| 2 | GLP-1 Now a Confirmed Tailwind | 3-year cohort data shows GLP-1s expand the top of the funnel and lift adherence — the feared substitute is now a driver. |
| 3 | EPS Compounding + GM Expansion to 2030 | Mid-teens EPS growth with gross margin expanding every year through 2030 — a powerful earnings-growth engine. |
| 4 | Net Cash, Clean Backdrop | Net-cash balance sheet, enlarged buyback, and a clean reimbursement/tariff backdrop. |
| 5 | Multiple Re-Rating Optionality | At ~17.9x forward P/E vs a ~20-22x peer band and ~30x own history, a re-rating as GLP-1 fear turns to fact compounds with EPS growth. |
| # | Factor | Detail |
|---|---|---|
| 1 | Philips US Device Re-Entry | An eventual Philips re-entry could pressure share/price; timing is unknown (per Philips itself), but it is a real overhang on the core franchise. |
| 2 | Maturing Core Growth | Decelerating ex-US device growth (5% cc in Q2 FY26, lumpy) and soft RCS growth (mid-single-digit) could signal the core is maturing. |
| 3 | Higher Tax Rate Caps EPS Leverage | The 21-23% effective tax rate (up from 18-19%) caps EPS leverage relative to prior years. |
| 4 | GLP-1 Long-Tail Risk | A tail risk that GLP-1s eventually reduce OSA severity/prevalence enough to slow new-patient flow — a risk management argues is now disproven. |
| 5 | Discount May Persist | The discounted multiple may reflect a market that views ResMed as a low-double-digit grower, not a re-rating candidate. |
Score of 7/10 reflects a favorable, asymmetric set-up with limited downside. On the rubric (no meaningful China exposure + valuation below peer + near-term catalysts + minimal regulatory risk), RMD lands solidly in the 7 zone.
What supports 7/10: Valuation below the MedTech peer average at ~17.9x forward FY2027 P/E versus a ~20-22x peer band — the most important rubric condition. China exposure immaterial (low-single-digit, sales channel only). Net-cash balance sheet. Regulatory overhang light and improving (CMS competitive-bidding exclusion, decades of tariff relief, US-manufacturing build-out). Multiple credible, management-backed catalysts (GLP-1 tailwind with 3-year data, annual GM expansion to 2030, new fabric-mask cycle, enlarged buyback).
Why not a 9-10: The catalysts are evolutionary rather than a single dated event. Philips' eventual US re-entry and a maturing ex-US/RCS growth profile are real, if manageable, bear arguments. The higher 21-23% tax rate modestly caps EPS leverage.
Net: ResMed is a high-quality leader trading at a discount to peers and its own history, with a benign risk profile and management-backed catalysts — an asymmetric, favorable configuration.